Judice Kevin

CEO, DirectorDICE Therapeutics, Inc. (DICE) · full profile →Form 4 · filed Aug 9, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
1 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 9, 2023Disposed to issuer(D)800K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 9, 2023Disposed to issuer(D)20K0
Aug 9, 2023Disposed to issuer(D)17K0
Aug 9, 2023Disposed to issuer(D)131K0
Aug 9, 2023Disposed to issuer(D)132K0
Aug 9, 2023Disposed to issuer(D)385K0
Aug 9, 2023Disposed to issuer(D)300K0
Aug 9, 2023Disposed to issuer(D)50K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-045172) within minutes of acceptance. Every field above traces to the original document. Verify it directly: